A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis

References

• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–659.
   PubMed Web of Science ®Google Scholar
• Levin E, Gupta R, Butler D, et al. Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression. J Dermatolog Treat. 2014;25:501–506.
   PubMed Web of Science ®Google Scholar
• Lam LH, Sugarman JL. Adrenal suppression with chronic topical corticosteroid use in psoriasis patients. J Drugs Dermatol. 2016;15:945–948.
   PubMed Web of Science ®Google Scholar
• Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012;26:36–46.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009–1016.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gelfand JM, Stein Gold L, et al. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007;79:18–31.
   PubMed Web of Science ®Google Scholar
• Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408–414.
   PubMed Web of Science ®Google Scholar
• Eastman WJ, Malahias S, Delconte J, et al. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014;94:46–53.
   PubMed Web of Science ®Google Scholar
• Lowe N, Feldman SR, Sherer D, et al. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat. 2005;16:158–164.
   PubMed Web of Science ®Google Scholar
• Greenspan A, Herndon JH, Jr, Baker MD, et al. Controlled evaluation of 0.05% desonide lotion and desonide cream in psoriasis. Curr Therapeu Res Clin Exp. 1993;53:614–620.
   Web of Science ®Google Scholar
• Decroix J, Pres H, Tsankov N, et al. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis. 2004;74:201–206.
   PubMed Web of Science ®Google Scholar
• Bernhard J, Whitmore C, Guzzo C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol. 1991;25:1170–1174.
   PubMed Web of Science ®Google Scholar
• Katz HI, Gross E, Buxman M, et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol. 1991;25:1175–1178.
   PubMed Web of Science ®Google Scholar
• Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25:1153–1156.
   PubMed Web of Science ®Google Scholar
• Goldberg B, Hartdegen R, Presbury D, et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25:1145–1148.
   PubMed Web of Science ®Google Scholar
• Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol. 1991;25:1149–1152.
   PubMed Web of Science ®Google Scholar
• Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25:1166–1169.
   PubMed Web of Science ®Google Scholar
• Pariser D, Bukhalo M, Guenthner S, et al. Two multicenter, randomized, double-blind, parallel group comparison studies of a novel enhanced lotion formulation of halobetasol propionate, 0.05% versus its vehicle in adult subjects with plaque psoriasis. J Drugs Dermatol. 2017;16:234–240.
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Gold LS, Lebwohl MG, et al. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16:611–618.
   Web of Science ®Google Scholar
• Dhurat R, AJ K, Vishwanath V, et al. Evaluation of the efficacy and safety of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in chronic, localized plaque psoriasis. Asian J Pharm Clin Res. 2016;9:288–291.
   Google Scholar
• Pariser DM, Green LJ, Cook Bolden F, et al. Efficacy of a halobetasol 0.01% lotion in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase III randomized controlled trials. Poster presented at Winter Clinical Dermatology Conference; 2018. January; Maui, HI.
   Google Scholar
• Ultravate (halobetasol propionate) 0.05%: summary of prescribing information. Jacksonville: Ranbaxy; 2012
   Google Scholar
• Brunner N, Yawalkar S. A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991;25:1160–1163.
   PubMed Web of Science ®Google Scholar
• Datz B, Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991;25:1157–1160.
   PubMed Web of Science ®Google Scholar
• Kantor I, Cook PR, Cullen SI, et al. Double-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses. J Am Acad Dermatol. 1991;25:1184–1186.
   PubMed Web of Science ®Google Scholar
• Yawalkar SJ, Schwerzmann L. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis. J Am Acad Dermatol. 1991;25:1163–1166.
   PubMed Web of Science ®Google Scholar
• Watson WA, Kalb RE, Siskin SB, et al. The safety of halobetasol 0.05% ointment in the treatment of psoriasis. Pharmacotherapy. 1990;10:107–111.
   PubMed Web of Science ®Google Scholar